董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert J. Coury | 男 | Chairman | 58 | 180.00万美元 | 146.63 | 2019-05-24 |
| Heather Bresch | 女 | Chief Executive Officer and Director | 49 | 1333.24万美元 | 84.29 | 2019-05-24 |
| 梅尔莫 | 女 | Director | 59 | 28.00万美元 | 未持股 | 2019-05-24 |
| Sjoerd S. Vollebregt | 男 | Director | 64 | 34.50万美元 | 未持股 | 2019-05-24 |
| Harry A. Korman | 男 | Director | 61 | 28.50万美元 | 未持股 | 2019-05-24 |
| Neil Dimick | 男 | Director | 69 | 39.13万美元 | 4.25 | 2019-05-24 |
| Rajiv Malik | 男 | President and Director | 58 | 950.66万美元 | 82.49 | 2019-05-24 |
| Robert J. Cindrich | 男 | Director | 75 | 35.88万美元 | 1.70 | 2019-05-24 |
| Randall L. Vanderveen | 男 | Director | 68 | 33.50万美元 | 3.97 | 2019-05-24 |
| Mark W. Parrish | 男 | Director | 63 | 46.88万美元 | 3.53 | 2019-05-24 |
| Melina Higgins | 女 | Director | 51 | 36.50万美元 | 7.94 | 2019-05-24 |
| JoEllen Lyons Dillon | 女 | Director | 55 | 40.50万美元 | 1.70 | 2019-05-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Heather Bresch | 女 | Chief Executive Officer and Director | 49 | 1333.24万美元 | 84.29 | 2019-05-24 |
| Kenneth S. Parks | 男 | Chief Financial Officer | 55 | 440.69万美元 | 0.14 | 2019-05-24 |
| Rajiv Malik | 男 | President and Director | 58 | 950.66万美元 | 82.49 | 2019-05-24 |
| Anthony Mauro | 男 | Chief Commercial Officer | 46 | 445.15万美元 | 15.62 | 2019-05-24 |
董事简历
中英对照 | 中文 | 英文- Robert J. Coury
-
Robert J. Coury， 自2009年5月起，他一直担任Mylan公司的董事会主席；自2012年1月1日起，担任执行主席。在担任主席之前，2002年3月他担任董事会副主席。2002年9月至2011年12月31日，他还担任Mylan公司的行政总裁。在他富有远见的领导下，Mylan公司转变为世界上标准普尔500指数和财富500强的公司。2007年，他领导公司通过竞争激烈的医药行业转型为一个全球性的公司。当时，Mylan公司是美国第三大仿制药生产商，通过购买印度的Matrix 实验室有限公司和 Mylan实验室有限公司（一家活性药物成分的主要生产国）以及Merck KGaA仿制药和专业制药企业，Mylan公司一跃进入全球前三名的仿制药公司。这些收购在很多关键领域给了公司前所未有的规模，其中包括广泛的国际商业印记。在Mylan公司之前，他是Coury咨询（他于1989年成立的一家精品商务咨询事务所）及Coury金融集团（1984年成立的一个成功的金融和地产规划公司）的主要负责人。通过这个专业经验，他磨练了他的创业人才和本能。
Robert J. Coury,has served as Viatris' Executive Chairman since the closing of the Combination on November 16, 2020. Mr. Coury leads the Board; oversees the strategic direction of the Company with the Board and in collaboration with executive management; advises the management team on important ongoing business matters, including as they execute on the Company's strategy to drive value creation and to otherwise unlock value; oversees management's execution of the business strategies approved by the Board; oversees executive talent management; and ensures robust engagement with shareholders and other key stakeholders, among other responsibilities.Mr. Coury most recently served as Executive Chairman of Mylan. During his tenure with Mylan, Mr. Coury's strategic vision led to the creation of a strong foundation for Viatris. Under Mr. Coury's leadership, Mylan grew from the third-largest generics pharmaceutical company in the United States to one of the largest pharmaceutical companies in the world, earning spots in both the S&P 500 and, prior to Mylan's reincorporation outside of the United States in 2015, the Fortune 500.Mr. Coury was first elected to Mylan's Board of Directors (the "Mylan Board") in February 2002, having served since 1995 as a strategic advisor to the company. He became the Vice Chairman shortly after his election and served as Chief Executive Officer from September 2002 until January 2012. He then served as Executive Chairman from 2012 until he became non-executive Chairman in June 2016. As Executive Chairman between 2012 and 2016, Mr. Coury's primary responsibilities were similar to those noted above. As non-executive Chairman, Mr. Coury continued to provide the overall strategic leadership for Mylan and was directly involved in shareholder engagement and material transactions involving Mylan, as well as in other matters considered significant by Mylan's Board. The Mylan Board reappointed Mr. Coury as Executive Chairman in April 2020. In that role, Mr. Coury's responsibilities were similar to his current responsibilities, and he provided leadership and strategic direction in navigating the unique challenges posed to Mylan and the pharmaceutical industry by the COVID-19 pandemic and oversight of work related to the Combination.Mr. Coury is the founder and president of the Robert J. Coury Family Foundation, which is a private foundation formed to help support his philanthropic efforts and his mission of giving back. He has served as a member of the University of Southern California President's Leadership Council since 2014. Mr. Coury also serves on the Goldman Sachs Healthcare Advisory Council. - Robert J. Coury， 自2009年5月起，他一直担任Mylan公司的董事会主席；自2012年1月1日起，担任执行主席。在担任主席之前，2002年3月他担任董事会副主席。2002年9月至2011年12月31日，他还担任Mylan公司的行政总裁。在他富有远见的领导下，Mylan公司转变为世界上标准普尔500指数和财富500强的公司。2007年，他领导公司通过竞争激烈的医药行业转型为一个全球性的公司。当时，Mylan公司是美国第三大仿制药生产商，通过购买印度的Matrix 实验室有限公司和 Mylan实验室有限公司（一家活性药物成分的主要生产国）以及Merck KGaA仿制药和专业制药企业，Mylan公司一跃进入全球前三名的仿制药公司。这些收购在很多关键领域给了公司前所未有的规模，其中包括广泛的国际商业印记。在Mylan公司之前，他是Coury咨询（他于1989年成立的一家精品商务咨询事务所）及Coury金融集团（1984年成立的一个成功的金融和地产规划公司）的主要负责人。通过这个专业经验，他磨练了他的创业人才和本能。
- Robert J. Coury,has served as Viatris' Executive Chairman since the closing of the Combination on November 16, 2020. Mr. Coury leads the Board; oversees the strategic direction of the Company with the Board and in collaboration with executive management; advises the management team on important ongoing business matters, including as they execute on the Company's strategy to drive value creation and to otherwise unlock value; oversees management's execution of the business strategies approved by the Board; oversees executive talent management; and ensures robust engagement with shareholders and other key stakeholders, among other responsibilities.Mr. Coury most recently served as Executive Chairman of Mylan. During his tenure with Mylan, Mr. Coury's strategic vision led to the creation of a strong foundation for Viatris. Under Mr. Coury's leadership, Mylan grew from the third-largest generics pharmaceutical company in the United States to one of the largest pharmaceutical companies in the world, earning spots in both the S&P 500 and, prior to Mylan's reincorporation outside of the United States in 2015, the Fortune 500.Mr. Coury was first elected to Mylan's Board of Directors (the "Mylan Board") in February 2002, having served since 1995 as a strategic advisor to the company. He became the Vice Chairman shortly after his election and served as Chief Executive Officer from September 2002 until January 2012. He then served as Executive Chairman from 2012 until he became non-executive Chairman in June 2016. As Executive Chairman between 2012 and 2016, Mr. Coury's primary responsibilities were similar to those noted above. As non-executive Chairman, Mr. Coury continued to provide the overall strategic leadership for Mylan and was directly involved in shareholder engagement and material transactions involving Mylan, as well as in other matters considered significant by Mylan's Board. The Mylan Board reappointed Mr. Coury as Executive Chairman in April 2020. In that role, Mr. Coury's responsibilities were similar to his current responsibilities, and he provided leadership and strategic direction in navigating the unique challenges posed to Mylan and the pharmaceutical industry by the COVID-19 pandemic and oversight of work related to the Combination.Mr. Coury is the founder and president of the Robert J. Coury Family Foundation, which is a private foundation formed to help support his philanthropic efforts and his mission of giving back. He has served as a member of the University of Southern California President's Leadership Council since 2014. Mr. Coury also serves on the Goldman Sachs Healthcare Advisory Council.
- Heather Bresch
-
Heather Bresch， 自2012年1月1日起，她一直担任Mylan的行政总裁（CEO）。在Mylan公司22年的职业生涯中，她曾在超过15个功能区担任越来越重要的角色。在成为CEO之前，2009年7月她担任Mylan的总裁，负责公司的日常的运作。在此之前，2007年10月至2009年7月她曾担任Mylan公司的首席营运官和首席整合官，引领了两个转型国际并购的成功整合—— Matrix实验室有限公司（Mylan公司实验室有限公司）和Merck KGaA 仿制药和特色制药企业（Merck Generics）。在她的领导下，Mylan公司继续扩大其投资组合及地理覆盖范围，收购可注射的产品和创新的呼吸技术平台的全球领先者；与生物和胰岛素产品组合合作；进入新的商业市场，例如印度和巴西；并通过新颖的测试设备的分布扩大其在艾滋病毒/艾滋病的治疗中的领导地位。
Heather Bresch has served as Mylan’s CEO since January 1 2012. She continues to lead the next chapter of Mylan’s growth and performance, pursuing a strategy that has produced a sustainable organization that is built for the long-term. Among many other areas of focus, Ms. Bresch is leading a business transformation initiative to further enhance the long-term success and sustainability of the Company, and continues to lead the diversification of the Company in terms of products, markets and channels, a process proven to expand access to the medicines upon which patients depend, while generating durable cash flows that can be reinvested to further differentiate and enhance Mylan’s business.Ms. Bresch is a recognized leader in the industry and a vocal champion of initiatives and policy changes aimed at removing access barriers. Among her policy priorities are increasing generic utilization, driving biosimilars interchangeability, stemming the tide of HIV/AIDS, ensuring a fair and a level playing field, and strengthening the global supply chain to make it safer for all patients. Additional details regarding Ms. Bresch’s background can be found on page 1. - Heather Bresch， 自2012年1月1日起，她一直担任Mylan的行政总裁（CEO）。在Mylan公司22年的职业生涯中，她曾在超过15个功能区担任越来越重要的角色。在成为CEO之前，2009年7月她担任Mylan的总裁，负责公司的日常的运作。在此之前，2007年10月至2009年7月她曾担任Mylan公司的首席营运官和首席整合官，引领了两个转型国际并购的成功整合—— Matrix实验室有限公司（Mylan公司实验室有限公司）和Merck KGaA 仿制药和特色制药企业（Merck Generics）。在她的领导下，Mylan公司继续扩大其投资组合及地理覆盖范围，收购可注射的产品和创新的呼吸技术平台的全球领先者；与生物和胰岛素产品组合合作；进入新的商业市场，例如印度和巴西；并通过新颖的测试设备的分布扩大其在艾滋病毒/艾滋病的治疗中的领导地位。
- Heather Bresch has served as Mylan’s CEO since January 1 2012. She continues to lead the next chapter of Mylan’s growth and performance, pursuing a strategy that has produced a sustainable organization that is built for the long-term. Among many other areas of focus, Ms. Bresch is leading a business transformation initiative to further enhance the long-term success and sustainability of the Company, and continues to lead the diversification of the Company in terms of products, markets and channels, a process proven to expand access to the medicines upon which patients depend, while generating durable cash flows that can be reinvested to further differentiate and enhance Mylan’s business.Ms. Bresch is a recognized leader in the industry and a vocal champion of initiatives and policy changes aimed at removing access barriers. Among her policy priorities are increasing generic utilization, driving biosimilars interchangeability, stemming the tide of HIV/AIDS, ensuring a fair and a level playing field, and strengthening the global supply chain to make it safer for all patients. Additional details regarding Ms. Bresch’s background can be found on page 1.
- 梅尔莫
-
梅尔莫女士自 2010 年起一直担任鹿特丹伊拉斯姆斯大学校长。她最初从事法律专业，1989 至 2004 年间曾在 Royal Dutch Shell Group 担任多个法律及管理职务，其后晋升为资讯科技部人力资源总监。2004 年，梅女士获委任为 TNT NV 集团人力资源总监。她于 2006 年出任 ABN AMRO Bank NV 的高级执行副总裁兼集团人力资源主管。2008 年，梅女士创办人力资本咨询公司，并于 2010 至 2013 年间出任荷兰银行业守则监察委员会（Dutch Banking Code Monitoring Commission）成员。此外，她也是 Royal DSM NV 和 ASML Holding NV 督导委员会成员。为汇丰控股有限公司独立非执行董事，由2015年9月1日起生效。
Pauline van der Meer Mohr,has served on the Board since the closing of the Combination on November 16, 2020. In April 2022, Ms. van der Meer Mohr became a member of the supervisory board of Koninklijke Ahold Delhaize N.V. (AMS: AD) and currently serves as Chair of its Remuneration Committee and a member of its Audit Committee. In September 2021, she became a member of the supervisory board of ASM International N.V. (AMS: ASMIY) and in April 2022 was appointed as Chairperson of the Supervisory Board and is a member of that company's Nomination, Selection and Remuneration Committee. Since January 2023, she has served on the Supervisory Board of Nationale- Nederlanden N.V. (AMS: NN), an international financial services company, and is a member of its Remuneration and Nomination and Corporate Governance Committees. Ms. van der Meer Mohr most recently served as a Director of HSBC Holdings plc (LON: HSBA), chairing that company's Group Remuneration Committee and serving as a member of its Group Audit Committee and Nomination & Corporate Governance Committee, until her retirement from this board in April 2022. From 2011 to May 2021, she was also a member of the supervisory board of Royal DSM N.V. (AMS: DSM), most recently serving as Deputy Chair, chairing its Remuneration Committee and serving on its Nomination Committee. She is also a member of the supervisory board of EY Netherlands LLP, currently serving as Chair. Ms. van der Meer Mohr also serves as the Chair of the Dutch Corporate Governance Code Monitoring Committee and as Chair of the Appointment Advisory Committee for the President of the Supreme Court of the Netherlands, and she is a member of the Capital Markets Committee of the Dutch Authority for Financial Markets. Previously, Ms. van der Meer Mohr served on the board of directors of Mylan from 2018 until the closing of the Combination, where she most recently served on the Compensation and Risk Oversight Committees. She also served on the supervisory board of ASML Holding N.V. (NASDAQ and AMS: ASML) from 2009 until April 2018, and as President of the executive board of Erasmus University in Rotterdam from 2010 to 2016. Ms. van der Meer Mohr began her career in the legal profession and previously held several legal and management positions at Royal Dutch Shell Group from 1989 to 2004. In 2004, she was appointed Group Human Resources Director at TNT N.V., now known as PostNL (AMS: PNL), before becoming Senior Executive Vice President and Head of Group Human Resources at ABN AMRO NV in 2006. She served as a member of the Dutch Banking Code Monitoring Commission in the Netherlands from 2010 to 2013, and began her own human capital consulting firm in 2008. - 梅尔莫女士自 2010 年起一直担任鹿特丹伊拉斯姆斯大学校长。她最初从事法律专业，1989 至 2004 年间曾在 Royal Dutch Shell Group 担任多个法律及管理职务，其后晋升为资讯科技部人力资源总监。2004 年，梅女士获委任为 TNT NV 集团人力资源总监。她于 2006 年出任 ABN AMRO Bank NV 的高级执行副总裁兼集团人力资源主管。2008 年，梅女士创办人力资本咨询公司，并于 2010 至 2013 年间出任荷兰银行业守则监察委员会（Dutch Banking Code Monitoring Commission）成员。此外，她也是 Royal DSM NV 和 ASML Holding NV 督导委员会成员。为汇丰控股有限公司独立非执行董事，由2015年9月1日起生效。
- Pauline van der Meer Mohr,has served on the Board since the closing of the Combination on November 16, 2020. In April 2022, Ms. van der Meer Mohr became a member of the supervisory board of Koninklijke Ahold Delhaize N.V. (AMS: AD) and currently serves as Chair of its Remuneration Committee and a member of its Audit Committee. In September 2021, she became a member of the supervisory board of ASM International N.V. (AMS: ASMIY) and in April 2022 was appointed as Chairperson of the Supervisory Board and is a member of that company's Nomination, Selection and Remuneration Committee. Since January 2023, she has served on the Supervisory Board of Nationale- Nederlanden N.V. (AMS: NN), an international financial services company, and is a member of its Remuneration and Nomination and Corporate Governance Committees. Ms. van der Meer Mohr most recently served as a Director of HSBC Holdings plc (LON: HSBA), chairing that company's Group Remuneration Committee and serving as a member of its Group Audit Committee and Nomination & Corporate Governance Committee, until her retirement from this board in April 2022. From 2011 to May 2021, she was also a member of the supervisory board of Royal DSM N.V. (AMS: DSM), most recently serving as Deputy Chair, chairing its Remuneration Committee and serving on its Nomination Committee. She is also a member of the supervisory board of EY Netherlands LLP, currently serving as Chair. Ms. van der Meer Mohr also serves as the Chair of the Dutch Corporate Governance Code Monitoring Committee and as Chair of the Appointment Advisory Committee for the President of the Supreme Court of the Netherlands, and she is a member of the Capital Markets Committee of the Dutch Authority for Financial Markets. Previously, Ms. van der Meer Mohr served on the board of directors of Mylan from 2018 until the closing of the Combination, where she most recently served on the Compensation and Risk Oversight Committees. She also served on the supervisory board of ASML Holding N.V. (NASDAQ and AMS: ASML) from 2009 until April 2018, and as President of the executive board of Erasmus University in Rotterdam from 2010 to 2016. Ms. van der Meer Mohr began her career in the legal profession and previously held several legal and management positions at Royal Dutch Shell Group from 1989 to 2004. In 2004, she was appointed Group Human Resources Director at TNT N.V., now known as PostNL (AMS: PNL), before becoming Senior Executive Vice President and Head of Group Human Resources at ABN AMRO NV in 2006. She served as a member of the Dutch Banking Code Monitoring Commission in the Netherlands from 2010 to 2013, and began her own human capital consulting firm in 2008.
- Sjoerd S. Vollebregt
-
Sjoerd S. Vollebregt，他一直担任Heijmans N.V。（阿姆斯特丹泛欧交易所上市公司，从事房地产开发、住宅建设、非住宅建筑、道路和土木工程等领域业务）的监事会主席（2015年以来），以及Airbus Defence and Space Netherlands B.V。（巴黎泛欧交易所上市公司Airbus SE的子公司，从事开发太阳能阵列、卫星仪器和发射器架构）的咨询委员会的主席（2015年以来）。他曾一直担任Stork B.V。（曾是阿姆斯特丹证券交易所上市工业集团，由知识维护、修改和资产完整性产品和服务、食品和纺织设备制造商组成的全球供应商，直到2008年）及其前身公司的执行委员会的董事长（2002年至2014年），以及Fokker Technologies Group B.V。（一家航空公司）和Stork B.V。子公司的首席执行官（2010年至2014年）。此前，他曾担任TNT Express N.V。（国际快递服务公司）的监事会成员（2013年至2016年），也曾担任Excel plc、Ocean plc、Intexo Holding、Royal Van Ommeren的多种其它高级职务。
Sjoerd S. Vollebregt has served as chairman of the Supervisory Board of Heijmans N.V., a Euronext Amsterdam listed company that operates in property development, residential building, non-residential building, roads and civil engineering, since 2015; chairman of the Advisory Board of Airbus Defence and Space Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris listed company, that develops solar arrays, satellite instruments and structures for launchers, since 2015; and chairman of the Economic Development Board Drecht Cities, a strategic collaboration between business, education and government in Drecht Cities, Netherlands, since December 2016. Mr. Vollebregt had served as chairman and chief executive officer of the Executive Board of Stork B.V. and its predecessor from 2002 to 2014 which was an Amsterdam Stock Exchange-listed industrial group until 2008 consisting of a global provider of knowledge-based maintenance, modification and asset integrity products and services for oil related industries, food and textile equipment manufacturer, and chief executive officer of Fokker Technologies Group B.V., an aerospace company and a Stork B.V. subsidiary from 2010 to 2014. Previously, Mr. Vollebregt served as a member of the Supervisory Board of TNT Express N.V., an international courier delivery services company, from 2013 to 2016 and has held various other senior positions at Exel plc, Ocean plc, Intexo Holding and Royal Van Ommeren. - Sjoerd S. Vollebregt，他一直担任Heijmans N.V。（阿姆斯特丹泛欧交易所上市公司，从事房地产开发、住宅建设、非住宅建筑、道路和土木工程等领域业务）的监事会主席（2015年以来），以及Airbus Defence and Space Netherlands B.V。（巴黎泛欧交易所上市公司Airbus SE的子公司，从事开发太阳能阵列、卫星仪器和发射器架构）的咨询委员会的主席（2015年以来）。他曾一直担任Stork B.V。（曾是阿姆斯特丹证券交易所上市工业集团，由知识维护、修改和资产完整性产品和服务、食品和纺织设备制造商组成的全球供应商，直到2008年）及其前身公司的执行委员会的董事长（2002年至2014年），以及Fokker Technologies Group B.V。（一家航空公司）和Stork B.V。子公司的首席执行官（2010年至2014年）。此前，他曾担任TNT Express N.V。（国际快递服务公司）的监事会成员（2013年至2016年），也曾担任Excel plc、Ocean plc、Intexo Holding、Royal Van Ommeren的多种其它高级职务。
- Sjoerd S. Vollebregt has served as chairman of the Supervisory Board of Heijmans N.V., a Euronext Amsterdam listed company that operates in property development, residential building, non-residential building, roads and civil engineering, since 2015; chairman of the Advisory Board of Airbus Defence and Space Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris listed company, that develops solar arrays, satellite instruments and structures for launchers, since 2015; and chairman of the Economic Development Board Drecht Cities, a strategic collaboration between business, education and government in Drecht Cities, Netherlands, since December 2016. Mr. Vollebregt had served as chairman and chief executive officer of the Executive Board of Stork B.V. and its predecessor from 2002 to 2014 which was an Amsterdam Stock Exchange-listed industrial group until 2008 consisting of a global provider of knowledge-based maintenance, modification and asset integrity products and services for oil related industries, food and textile equipment manufacturer, and chief executive officer of Fokker Technologies Group B.V., an aerospace company and a Stork B.V. subsidiary from 2010 to 2014. Previously, Mr. Vollebregt served as a member of the Supervisory Board of TNT Express N.V., an international courier delivery services company, from 2013 to 2016 and has held various other senior positions at Exel plc, Ocean plc, Intexo Holding and Royal Van Ommeren.
- Harry A. Korman
-
Harry A. Korman从1996年到2014年7月在Mylan公司及其子公司担任高级执行官，负责增加职责。2012年1月至2014年7月，他担任Mylan Inc.的全球首席运营官，之后在Mylan Inc.担任顾问一年。在担任首席运营官之前，他从2007年10月开始担任Mylan公司北美区总裁。2005年2月至2009年12月，Korman先生还担任Mylan Pharmaceuticals Inc.的总裁。Korman先生在Mylan担任执行官期间，在识别、评估和执行美国和其他国家的重大商业和商业发展机会方面发挥了重要作用，包括在世界各地扩展Mylan的全球仿制药业务，对公司及其利益相关者的许多其他重要贡献。他于1996年加入Mylan，此前公司收购了Udl Laboratories，Inc.N/K/A Mylan Institutional Inc.，并担任公司总裁。科曼先生曾担任仿制药协会（现称为无障碍药物协会）的前任董事和副主席。他还曾担任董事会和副主席的HDMA基金会，服务于医疗保健行业提供研究和教育集中在医疗保健供应问题。
Harry A. Korman,Held senior executive roles of increasing responsibility, including Global Chief Operating Officer (2012-2014, after which he served as a consultant (2014-2015)), President, North America (2007-2012), President, Mylan Pharmaceuticals Inc. (2005-2009); joined in 1996 after the company's acquisition of UDL Laboratories, Inc. (n/k/a Mylan Institutional Inc.), Mylan Inc.Public Company Management, Corporate Governance/CSR, Healthcare Industry, Risk Oversight/Compliance, Strategy and M&A, and Global Business Experience gained during his almost 20 years serving in leadership roles at Mylan, where he helped grow their generics business and ultimately had responsibility for all operations as Global Chief Operating Officer. - Harry A. Korman从1996年到2014年7月在Mylan公司及其子公司担任高级执行官，负责增加职责。2012年1月至2014年7月，他担任Mylan Inc.的全球首席运营官，之后在Mylan Inc.担任顾问一年。在担任首席运营官之前，他从2007年10月开始担任Mylan公司北美区总裁。2005年2月至2009年12月，Korman先生还担任Mylan Pharmaceuticals Inc.的总裁。Korman先生在Mylan担任执行官期间，在识别、评估和执行美国和其他国家的重大商业和商业发展机会方面发挥了重要作用，包括在世界各地扩展Mylan的全球仿制药业务，对公司及其利益相关者的许多其他重要贡献。他于1996年加入Mylan，此前公司收购了Udl Laboratories，Inc.N/K/A Mylan Institutional Inc.，并担任公司总裁。科曼先生曾担任仿制药协会（现称为无障碍药物协会）的前任董事和副主席。他还曾担任董事会和副主席的HDMA基金会，服务于医疗保健行业提供研究和教育集中在医疗保健供应问题。
- Harry A. Korman,Held senior executive roles of increasing responsibility, including Global Chief Operating Officer (2012-2014, after which he served as a consultant (2014-2015)), President, North America (2007-2012), President, Mylan Pharmaceuticals Inc. (2005-2009); joined in 1996 after the company's acquisition of UDL Laboratories, Inc. (n/k/a Mylan Institutional Inc.), Mylan Inc.Public Company Management, Corporate Governance/CSR, Healthcare Industry, Risk Oversight/Compliance, Strategy and M&A, and Global Business Experience gained during his almost 20 years serving in leadership roles at Mylan, where he helped grow their generics business and ultimately had responsibility for all operations as Global Chief Operating Officer.
- Neil Dimick
-
Neil Dimick， 他目前已退休。2001年至2002年，他曾担任AmerisourceBergen公司（纽约证券交易所代码：ABC）—— 一家药品批发分销商的执行副总裁兼首席财务官。1992年至2001年，他曾担任Bergen Brunswig公司（一家药品批发分销商）的高级执行副总裁兼首席财务官。在那之前的经验，他当了8年德勤会计师事务所的合伙人。他还担任WebMD 健康公司（纳斯达克股票代码：WBMD）、Thoratec公司（纳斯达克股票代码：THOR）、联盟医疗保健服务有限公司（纳斯达克股票代码：AIQ），和资源连接公司（纳斯达克股票代码：RECN）的董事会成员。2002年至2009年，他担任HLTH股份有限公司的董事会成员，当时它被并入WebMD健康公司。
Neil Dimick has served on the Viatris Board since the closing of the Combination on November 16 2020. Mr. Dimick has served on the board of directors of Resources Connection, Inc. NASDAQ: RECN since November 2003 and chairs its Audit Committee and serves on its Compensation Committee. Mr. Dimick previously served as a Director of Mylan from 2005 until the closing of the Combination, most recently chairing the Audit Committee and serving as a member of the Executive, Finance, and Risk Oversight Committees. Mr. Dimick served as Executive Vice President and Chief Financial Officer of AmerisourceBergen Corporation (NYSE: ABC), a wholesale distributor of pharmaceuticals, from 2001 to 2002. From 1992 to 2001 he was Senior Executive Vice President and Chief Financial Officer of Bergen Brunswig Corporation, a wholesale drug distributor. Prior to that, Mr. Dimick was a Partner with Deloitte for eight years. Mr. Dimick also served on the boards of directors of WebMD Health Corp. from 2005 to September 2017; Alliance HealthCare Services, Inc. from 2002 to August 2017; and Thoratec Corporation from 2003 to October 2015. - Neil Dimick， 他目前已退休。2001年至2002年，他曾担任AmerisourceBergen公司（纽约证券交易所代码：ABC）—— 一家药品批发分销商的执行副总裁兼首席财务官。1992年至2001年，他曾担任Bergen Brunswig公司（一家药品批发分销商）的高级执行副总裁兼首席财务官。在那之前的经验，他当了8年德勤会计师事务所的合伙人。他还担任WebMD 健康公司（纳斯达克股票代码：WBMD）、Thoratec公司（纳斯达克股票代码：THOR）、联盟医疗保健服务有限公司（纳斯达克股票代码：AIQ），和资源连接公司（纳斯达克股票代码：RECN）的董事会成员。2002年至2009年，他担任HLTH股份有限公司的董事会成员，当时它被并入WebMD健康公司。
- Neil Dimick has served on the Viatris Board since the closing of the Combination on November 16 2020. Mr. Dimick has served on the board of directors of Resources Connection, Inc. NASDAQ: RECN since November 2003 and chairs its Audit Committee and serves on its Compensation Committee. Mr. Dimick previously served as a Director of Mylan from 2005 until the closing of the Combination, most recently chairing the Audit Committee and serving as a member of the Executive, Finance, and Risk Oversight Committees. Mr. Dimick served as Executive Vice President and Chief Financial Officer of AmerisourceBergen Corporation (NYSE: ABC), a wholesale distributor of pharmaceuticals, from 2001 to 2002. From 1992 to 2001 he was Senior Executive Vice President and Chief Financial Officer of Bergen Brunswig Corporation, a wholesale drug distributor. Prior to that, Mr. Dimick was a Partner with Deloitte for eight years. Mr. Dimick also served on the boards of directors of WebMD Health Corp. from 2005 to September 2017; Alliance HealthCare Services, Inc. from 2002 to August 2017; and Thoratec Corporation from 2003 to October 2015.
- Rajiv Malik
-
Rajiv Malik， 自2012年1月1日起，他曾担任Mylan公司的总裁。此前，他曾在Mylan公司担任多个高级职务，包括2009年7月至2012年12月，担任全球技术运营部主管；2007年1月至2009年7月，担任执行副总裁兼首席营运官。 除了担任总裁监督公司的日常运作外，他一直在识别、评估和执行上有显著业务的发展机会，扩大和优化Mylan的产品组合，并利用Mylan公司的全球研究和开发能力等其他重要的贡献。此前，2005年7月至2008年6月他曾担任Matrix实验室有限公司和Mylan公司实验室有限公司的行政总裁。加入Matrix之前，2003年9月至2005年7月他曾担任Sandoz GmbH公司全球开发和注册的负责人。加入Sandoz之前，1999年10月至2003年9月，他担任Ranbaxy全球法规事务和制药研究部的主管。
Rajiv Malik,Retired President (from the closing of the Combination in 2020 to April 2024), Viatris;President (2012-the closing of the Combination in 2020), Executive Vice President and Chief Operating Officer (2009-2012), Head of Global Technical Operations (2007-2009); joined the company in 2007, Mylan;Chief Executive Officer (2005-2008), Matrix Laboratories Limited (now Mylan Laboratories Limited);Head of Global Development and Registrations (2003-2005), Sandoz GmbH;Head of Global Regulatory Affairs and Head of Pharma Research (1999-2003), Ranbaxy.Public Company Management, Finance, Accounting and Capital Markets, Healthcare Industry, Information Security, Legal and Regulatory Oversight, Risk Oversight/Compliance, Strategy and M&A, and Global Business Experience acquired over his extensive career in the healthcare industry, including at Mylan where he was integral in helping to develop the strategies for the company's acquisitions for over 10 years, as well as the execution and integration of those acquisitions, and was responsible for leading global commercial, scientific, operational, IT and business development activities in more than 165 countries and territories, a portfolio of more than 7,500 products, a pipeline of approximately 1,200 products, and more than 40 manufacturing facilities around the world and further enhanced in his most recent role, where he was responsible for the day-to-day operations of the Company, overseeing the Company's commercial business units, the Commercial Development, Medical, IT and Quality functions, as well as R&D and Operations and where he played a leading role in integrating the two legacy companies while stabilizing the business until his retirement in April 2024.Mr. - Rajiv Malik， 自2012年1月1日起，他曾担任Mylan公司的总裁。此前，他曾在Mylan公司担任多个高级职务，包括2009年7月至2012年12月，担任全球技术运营部主管；2007年1月至2009年7月，担任执行副总裁兼首席营运官。 除了担任总裁监督公司的日常运作外，他一直在识别、评估和执行上有显著业务的发展机会，扩大和优化Mylan的产品组合，并利用Mylan公司的全球研究和开发能力等其他重要的贡献。此前，2005年7月至2008年6月他曾担任Matrix实验室有限公司和Mylan公司实验室有限公司的行政总裁。加入Matrix之前，2003年9月至2005年7月他曾担任Sandoz GmbH公司全球开发和注册的负责人。加入Sandoz之前，1999年10月至2003年9月，他担任Ranbaxy全球法规事务和制药研究部的主管。
- Rajiv Malik,Retired President (from the closing of the Combination in 2020 to April 2024), Viatris;President (2012-the closing of the Combination in 2020), Executive Vice President and Chief Operating Officer (2009-2012), Head of Global Technical Operations (2007-2009); joined the company in 2007, Mylan;Chief Executive Officer (2005-2008), Matrix Laboratories Limited (now Mylan Laboratories Limited);Head of Global Development and Registrations (2003-2005), Sandoz GmbH;Head of Global Regulatory Affairs and Head of Pharma Research (1999-2003), Ranbaxy.Public Company Management, Finance, Accounting and Capital Markets, Healthcare Industry, Information Security, Legal and Regulatory Oversight, Risk Oversight/Compliance, Strategy and M&A, and Global Business Experience acquired over his extensive career in the healthcare industry, including at Mylan where he was integral in helping to develop the strategies for the company's acquisitions for over 10 years, as well as the execution and integration of those acquisitions, and was responsible for leading global commercial, scientific, operational, IT and business development activities in more than 165 countries and territories, a portfolio of more than 7,500 products, a pipeline of approximately 1,200 products, and more than 40 manufacturing facilities around the world and further enhanced in his most recent role, where he was responsible for the day-to-day operations of the Company, overseeing the Company's commercial business units, the Commercial Development, Medical, IT and Quality functions, as well as R&D and Operations and where he played a leading role in integrating the two legacy companies while stabilizing the business until his retirement in April 2024.Mr.
- Robert J. Cindrich
-
Robert J. Cindrich自2011年2月起，他一直担任Cindrich咨询有限责任公司的总裁—— 一家企业和医疗保健咨询公司，为客户提供有关公司治理、合规性和业务策略。2013年10月1日至2014年1月31日，他担任美国钢铁公司（纽约证券交易所代码：X）的临时总顾问。2013年4月他加入Schnader Harrison Segal & Lewis公司（一家律师事务所），担任法律顾问，2013年10月1日临时请假，作为临时总顾问加入美国钢铁公司。在2012年5月，他加入Allscripts医疗保健解决方案有限公司（ NASDAQ：MDRX） 的董事会，它提供医疗信息技术解决方案。2011年至2012年，他担任美国匹兹堡大学医学中心（UPMC）的高级顾问，是一家集成的全球健康企业。2004年至2010年，他担任UPMC的高级副总裁兼首席法务官。1994年至2004年1月，他担任美国地区法院宾夕法尼亚西区的法官。在任命前，他活跃在政府和私人执业，其中包括宾夕法尼亚西区美国律师和阿勒格尼县助理公共辩护律师和地区助理检察官。
Robert J. Cindrich,Since February 2011 Judge Cindrich has been serving as president of Cindrich Consulting, LLC, a business and healthcare consulting company that advises clients on corporate governance, compliance and business strategies. From October 1 2013 through January 31 2014 he served as interim general counsel for United States Steel Corporation "U.S. Steel" NYSE: X, an integrated steel producer of flat-rolled and tubular products. Judge Cindrich joined Schnader Harrison Segal & Lewis "Schnader", a law firm, as legal counsel in April 2013 and took a temporary leave of absence on October 1 2013 to join U.S. Steel as interim general counsel, returning to Schnader after his time there and remaining until December 2017. In May 2012 he joined the board of directors of Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), which provides healthcare information technology solutions, where he served until April 2015. From 2011 through 2012 Judge Cindrich served as a senior advisor to the Office of the President of the University of Pittsburgh Medical Center ("UPMC"), an integrated global health enterprise. From 2004 through 2010 Judge Cindrich was a senior vice president and the chief legal officer of UPMC. From 1994 through January 2004 Judge Cindrich served as a judge on the U.S. District Court for the Western District of Pennsylvania. Prior to that appointment, he was active as an attorney in government and private practice, including positions as the U.S. Attorney for the Western District of Pennsylvania and as the Allegheny County Assistant Public Defender and Assistant District Attorney. - Robert J. Cindrich自2011年2月起，他一直担任Cindrich咨询有限责任公司的总裁—— 一家企业和医疗保健咨询公司，为客户提供有关公司治理、合规性和业务策略。2013年10月1日至2014年1月31日，他担任美国钢铁公司（纽约证券交易所代码：X）的临时总顾问。2013年4月他加入Schnader Harrison Segal & Lewis公司（一家律师事务所），担任法律顾问，2013年10月1日临时请假，作为临时总顾问加入美国钢铁公司。在2012年5月，他加入Allscripts医疗保健解决方案有限公司（ NASDAQ：MDRX） 的董事会，它提供医疗信息技术解决方案。2011年至2012年，他担任美国匹兹堡大学医学中心（UPMC）的高级顾问，是一家集成的全球健康企业。2004年至2010年，他担任UPMC的高级副总裁兼首席法务官。1994年至2004年1月，他担任美国地区法院宾夕法尼亚西区的法官。在任命前，他活跃在政府和私人执业，其中包括宾夕法尼亚西区美国律师和阿勒格尼县助理公共辩护律师和地区助理检察官。
- Robert J. Cindrich,Since February 2011 Judge Cindrich has been serving as president of Cindrich Consulting, LLC, a business and healthcare consulting company that advises clients on corporate governance, compliance and business strategies. From October 1 2013 through January 31 2014 he served as interim general counsel for United States Steel Corporation "U.S. Steel" NYSE: X, an integrated steel producer of flat-rolled and tubular products. Judge Cindrich joined Schnader Harrison Segal & Lewis "Schnader", a law firm, as legal counsel in April 2013 and took a temporary leave of absence on October 1 2013 to join U.S. Steel as interim general counsel, returning to Schnader after his time there and remaining until December 2017. In May 2012 he joined the board of directors of Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), which provides healthcare information technology solutions, where he served until April 2015. From 2011 through 2012 Judge Cindrich served as a senior advisor to the Office of the President of the University of Pittsburgh Medical Center ("UPMC"), an integrated global health enterprise. From 2004 through 2010 Judge Cindrich was a senior vice president and the chief legal officer of UPMC. From 1994 through January 2004 Judge Cindrich served as a judge on the U.S. District Court for the Western District of Pennsylvania. Prior to that appointment, he was active as an attorney in government and private practice, including positions as the U.S. Attorney for the Western District of Pennsylvania and as the Allegheny County Assistant Public Defender and Assistant District Attorney.
- Randall L. Vanderveen
-
Randall L. Vanderveen自2005年9月起，担任南加州大学药学院的院长。并在2013年被美国药剂师协会评为“国家优秀药剂院长”。1998年至2005年，他曾担任杜肯大学制药科学研究生院管理学院院长与药学教授。在1988年至1998年之前他是俄勒冈州立大学院长助理、副教授。他有广泛的制药和学术背景。此外，他在Mylan公司董事会任期内对，给公司带来了大规模的增长。他获得了有关业务、平台策略、挑战、机遇以及公司管理等事项的宝贵经验。
Randall L. Vanderveen was Professor of Pharmaceutical Policy and Economics, Senior Adviser to the Leonard D. Schaeffer Center of Health Policy and Economics, Director of the Margaret and John Biles Center for Leadership, and Senior Adviser to the Dean for Advancement at the School of Pharmacy, University of Southern California in Los Angeles, California from 2015 to August 2017. Dr. Vanderveen previously served as Dean, Professor and John Stauffer Decanal Chair of the USC School of Pharmacy from 2005 to 2015 where he was named "Outstanding Pharmacy Dean in the Nation" in 2013 by the American Pharmacist Association. From 1998 to 2005 he served as Dean and Professor of Pharmacy of the School of Pharmacy and the Graduate School of Pharmaceutical Sciences at Duquesne University, before which he was Assistant Dean at Oregon State University from 1988 to 1998. - Randall L. Vanderveen自2005年9月起，担任南加州大学药学院的院长。并在2013年被美国药剂师协会评为“国家优秀药剂院长”。1998年至2005年，他曾担任杜肯大学制药科学研究生院管理学院院长与药学教授。在1988年至1998年之前他是俄勒冈州立大学院长助理、副教授。他有广泛的制药和学术背景。此外，他在Mylan公司董事会任期内对，给公司带来了大规模的增长。他获得了有关业务、平台策略、挑战、机遇以及公司管理等事项的宝贵经验。
- Randall L. Vanderveen was Professor of Pharmaceutical Policy and Economics, Senior Adviser to the Leonard D. Schaeffer Center of Health Policy and Economics, Director of the Margaret and John Biles Center for Leadership, and Senior Adviser to the Dean for Advancement at the School of Pharmacy, University of Southern California in Los Angeles, California from 2015 to August 2017. Dr. Vanderveen previously served as Dean, Professor and John Stauffer Decanal Chair of the USC School of Pharmacy from 2005 to 2015 where he was named "Outstanding Pharmacy Dean in the Nation" in 2013 by the American Pharmacist Association. From 1998 to 2005 he served as Dean and Professor of Pharmacy of the School of Pharmacy and the Graduate School of Pharmaceutical Sciences at Duquesne University, before which he was Assistant Dean at Oregon State University from 1988 to 1998.
- Mark W. Parrish
-
Mark W. Parrish，他一直担任Omnicell的董事（自2013年1月以来）。自2008年以来，他担任TridentUSA Health Services（为长期护理行业提供移动x射线及实验室服务的供应商）的主席兼首席执行官。2001年初，他担任Cardinal Health Inc.和其附属公司的管理职务并不断被提拔，包括Cardinal Health 的首席执行官（2006年到2007年）负责医疗供应链服务。他担任Mylan Inc.（一个全球制药公司）的董事、医药批发商国际联合会（the International Federation of Pharmaceutical Wholesalers）（一个药品批发商和药品供应链服务公司的协会）的主席和Frazier Healthcare Ventures（面向医疗的发展股权投资公司）的高级顾问。他获得了伯克利的Southern California大学的学士学位。
Mark W. Parrish,has served as a director of Omnicell since January 2013. Mr. Parrish served as Chief Executive Officer of TridentUSA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry, from 2008 to August 2018, and as Executive Chairman of TridentUSA Health Service from August 2018 to September 2019. In February 2019, TridentUSA Health Services filed for protection under Chapter 11 of the U.S. Bankruptcy Code. Commencing in 1993, Mr. Parrish held management roles of increasing significance with Cardinal Health Inc. and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as a director and Vice Chairman of Viatris, Inc. (formerly, Mylan N.V.), a global pharmaceutical company, as the Chairman of Safecor, a privately held hospital services firm, as President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies, and is a senior adviser to Frazier Healthcare Ventures, a health-care oriented growth equity firm. Mr. Parrish received a B.A. from the University of California, Berkeley. - Mark W. Parrish，他一直担任Omnicell的董事（自2013年1月以来）。自2008年以来，他担任TridentUSA Health Services（为长期护理行业提供移动x射线及实验室服务的供应商）的主席兼首席执行官。2001年初，他担任Cardinal Health Inc.和其附属公司的管理职务并不断被提拔，包括Cardinal Health 的首席执行官（2006年到2007年）负责医疗供应链服务。他担任Mylan Inc.（一个全球制药公司）的董事、医药批发商国际联合会（the International Federation of Pharmaceutical Wholesalers）（一个药品批发商和药品供应链服务公司的协会）的主席和Frazier Healthcare Ventures（面向医疗的发展股权投资公司）的高级顾问。他获得了伯克利的Southern California大学的学士学位。
- Mark W. Parrish,has served as a director of Omnicell since January 2013. Mr. Parrish served as Chief Executive Officer of TridentUSA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry, from 2008 to August 2018, and as Executive Chairman of TridentUSA Health Service from August 2018 to September 2019. In February 2019, TridentUSA Health Services filed for protection under Chapter 11 of the U.S. Bankruptcy Code. Commencing in 1993, Mr. Parrish held management roles of increasing significance with Cardinal Health Inc. and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as a director and Vice Chairman of Viatris, Inc. (formerly, Mylan N.V.), a global pharmaceutical company, as the Chairman of Safecor, a privately held hospital services firm, as President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies, and is a senior adviser to Frazier Healthcare Ventures, a health-care oriented growth equity firm. Mr. Parrish received a B.A. from the University of California, Berkeley.
- Melina Higgins
-
Melina Higgins，她目前已退休，她在Goldman Sachs集团有限公司（纽约证券交易所代码：GS-PC）担任越来越重要的高级职务，包括在她近20年的职业生涯中担任企业合伙人兼董事总经理。在Goldman Sachs任职期间，她担任首席投资区投资委员会的成员，它负责监督和批准全球私人股本和私人债务投资，是世界上最大的另类资产管理公司之一。她还担任过GS Mezzanine合伙人基金美洲的高管和投资咨询委员会的联合主席，管理300多亿资产，并是他们的全球行业领导者。2013年9月，她加入Genworth金融有限公司（纽约证券交易所代码：GNW）——是一家金融担保公司的董事会成员。
Melina Higgins,Held senior roles of increasing responsibility including Partner (2002-2010) and Managing Director (2001-2010) and served as a member of the Investment Committee of the Principal Investment Area, Head of the Americas for Private Debt and co-Chairperson of the Investment Advisory Committee for GS Mezzanine Partners funds, The Goldman Sachs Group, Inc. (NYSE: GS).Corporate Governance, Finance, Accounting and Capital Markets, Global Business, Risk Oversight/Compliance, and Strategy and M&A Experience obtained during her nearly 20 years at Goldman Sachs, where she built and led a successful investment business and became well-versed in portfolio management, assessing market risks and building businesses, especially during her time as a member of Goldman's Investment Committee of the Principal Investment Area, one of the largest alternative asset managers in the world, where she oversaw and approved global private equity and private debt investments. - Melina Higgins，她目前已退休，她在Goldman Sachs集团有限公司（纽约证券交易所代码：GS-PC）担任越来越重要的高级职务，包括在她近20年的职业生涯中担任企业合伙人兼董事总经理。在Goldman Sachs任职期间，她担任首席投资区投资委员会的成员，它负责监督和批准全球私人股本和私人债务投资，是世界上最大的另类资产管理公司之一。她还担任过GS Mezzanine合伙人基金美洲的高管和投资咨询委员会的联合主席，管理300多亿资产，并是他们的全球行业领导者。2013年9月，她加入Genworth金融有限公司（纽约证券交易所代码：GNW）——是一家金融担保公司的董事会成员。
- Melina Higgins,Held senior roles of increasing responsibility including Partner (2002-2010) and Managing Director (2001-2010) and served as a member of the Investment Committee of the Principal Investment Area, Head of the Americas for Private Debt and co-Chairperson of the Investment Advisory Committee for GS Mezzanine Partners funds, The Goldman Sachs Group, Inc. (NYSE: GS).Corporate Governance, Finance, Accounting and Capital Markets, Global Business, Risk Oversight/Compliance, and Strategy and M&A Experience obtained during her nearly 20 years at Goldman Sachs, where she built and led a successful investment business and became well-versed in portfolio management, assessing market risks and building businesses, especially during her time as a member of Goldman's Investment Committee of the Principal Investment Area, one of the largest alternative asset managers in the world, where she oversaw and approved global private equity and private debt investments.
- JoEllen Lyons Dillon
-
JoEllen Lyons Dillon自2020年11月16日重组完成后，一直在Viatris董事会任职。Dillon女士于2022年9月成为综合媒体和娱乐公司World Wrestling Entertainment，Inc. NYSE：WWE的董事会成员。Dillon女士从2014年起一直担任Mylan的董事，直到合并结束，最近担任薪酬、治理和提名委员会的主席，并担任审计、合规和执行委员会的成员。2013年3月至2017年8月，她担任三维印刷机和服务的全球供应商ExOne公司的执行干事。她于2014年12月晋升为执行副总裁，并在原有职责范围内担任首席法律干事和公司秘书。除其他外，她负责资本市场发展、公司战略规划、人力资源、全球合规、投资者关系以及欧洲和亚洲的国际业务发展。此前，Dillon女士在公司并购和证券领域拥有近25年的法律职业生涯，曾代表上市公司和私营公司处理各种复杂事务。从2002年到2011年，她是律师事务所Reed Smith LLP的合伙人。从1988年到2002年，她一直在Buchanan Ingersoll & Rooney PC律师事务所工作，并于1997年成为合伙人。Dillon女士曾担任国家多发性硬化症学会阿勒格尼区分会董事会成员，并担任主席和审计委员会主席。
JoEllen Lyons Dillon,Executive Vice President, Strategic Developments and Capital Markets (2014-2017); Chief Legal Officer and Corporate Secretary, The ExOne Company (2013-2017). ExOne merged with Desktop Metal (NYSE: DM) in November 2021. ExOne was a global provider of three-dimensional (3D) printing machines and printed products, materials and other services to industrial customers creating products in metal on a worldwide basis.Partner (2002-2011), Reed Smith LLP, a law firm.Partner (1997-2002), Buchanan Ingersoll & Rooney PC, a law firm (joined the firm in 1988).Public Company Management, Corporate Governance, Finance, Accounting and Capital Markets, Global Business, Human Capital Management, Information Security, Legal and Regulatory Oversight, Risk Oversight/Compliance, and Strategy and M&A Experience gained during her almost 25-year legal career in corporate M&A and securities, where she represented both public and private companies in a variety of complex matters, and further developed while at ExOne, where she was responsible for capital markets development, corporate strategic planning, human resources including oversight of diversity, equity and inclusion ("DEI"), global compliance, investor relations, and international business development within Europe and Asia, through which she became a thought leader in the areas of corporate governance, legal and regulatory oversight, capital markets and M&A and is regularly invited to speak at major conferences, including, among others, the 2023 Stanford Directors' College, on such topics.Completing a certification "Board Governance: Navigating Emerging Technologies and Future Frontiers" at Cornell University.CSR Experience obtained through her legal and regulatory background, in addition to ongoing education programs. - JoEllen Lyons Dillon自2020年11月16日重组完成后，一直在Viatris董事会任职。Dillon女士于2022年9月成为综合媒体和娱乐公司World Wrestling Entertainment，Inc. NYSE：WWE的董事会成员。Dillon女士从2014年起一直担任Mylan的董事，直到合并结束，最近担任薪酬、治理和提名委员会的主席，并担任审计、合规和执行委员会的成员。2013年3月至2017年8月，她担任三维印刷机和服务的全球供应商ExOne公司的执行干事。她于2014年12月晋升为执行副总裁，并在原有职责范围内担任首席法律干事和公司秘书。除其他外，她负责资本市场发展、公司战略规划、人力资源、全球合规、投资者关系以及欧洲和亚洲的国际业务发展。此前，Dillon女士在公司并购和证券领域拥有近25年的法律职业生涯，曾代表上市公司和私营公司处理各种复杂事务。从2002年到2011年，她是律师事务所Reed Smith LLP的合伙人。从1988年到2002年，她一直在Buchanan Ingersoll & Rooney PC律师事务所工作，并于1997年成为合伙人。Dillon女士曾担任国家多发性硬化症学会阿勒格尼区分会董事会成员，并担任主席和审计委员会主席。
- JoEllen Lyons Dillon,Executive Vice President, Strategic Developments and Capital Markets (2014-2017); Chief Legal Officer and Corporate Secretary, The ExOne Company (2013-2017). ExOne merged with Desktop Metal (NYSE: DM) in November 2021. ExOne was a global provider of three-dimensional (3D) printing machines and printed products, materials and other services to industrial customers creating products in metal on a worldwide basis.Partner (2002-2011), Reed Smith LLP, a law firm.Partner (1997-2002), Buchanan Ingersoll & Rooney PC, a law firm (joined the firm in 1988).Public Company Management, Corporate Governance, Finance, Accounting and Capital Markets, Global Business, Human Capital Management, Information Security, Legal and Regulatory Oversight, Risk Oversight/Compliance, and Strategy and M&A Experience gained during her almost 25-year legal career in corporate M&A and securities, where she represented both public and private companies in a variety of complex matters, and further developed while at ExOne, where she was responsible for capital markets development, corporate strategic planning, human resources including oversight of diversity, equity and inclusion ("DEI"), global compliance, investor relations, and international business development within Europe and Asia, through which she became a thought leader in the areas of corporate governance, legal and regulatory oversight, capital markets and M&A and is regularly invited to speak at major conferences, including, among others, the 2023 Stanford Directors' College, on such topics.Completing a certification "Board Governance: Navigating Emerging Technologies and Future Frontiers" at Cornell University.CSR Experience obtained through her legal and regulatory background, in addition to ongoing education programs.
高管简历
中英对照 | 中文 | 英文- Heather Bresch
Heather Bresch， 自2012年1月1日起，她一直担任Mylan的行政总裁（CEO）。在Mylan公司22年的职业生涯中，她曾在超过15个功能区担任越来越重要的角色。在成为CEO之前，2009年7月她担任Mylan的总裁，负责公司的日常的运作。在此之前，2007年10月至2009年7月她曾担任Mylan公司的首席营运官和首席整合官，引领了两个转型国际并购的成功整合—— Matrix实验室有限公司（Mylan公司实验室有限公司）和Merck KGaA 仿制药和特色制药企业（Merck Generics）。在她的领导下，Mylan公司继续扩大其投资组合及地理覆盖范围，收购可注射的产品和创新的呼吸技术平台的全球领先者；与生物和胰岛素产品组合合作；进入新的商业市场，例如印度和巴西；并通过新颖的测试设备的分布扩大其在艾滋病毒/艾滋病的治疗中的领导地位。
Heather Bresch has served as Mylan’s CEO since January 1 2012. She continues to lead the next chapter of Mylan’s growth and performance, pursuing a strategy that has produced a sustainable organization that is built for the long-term. Among many other areas of focus, Ms. Bresch is leading a business transformation initiative to further enhance the long-term success and sustainability of the Company, and continues to lead the diversification of the Company in terms of products, markets and channels, a process proven to expand access to the medicines upon which patients depend, while generating durable cash flows that can be reinvested to further differentiate and enhance Mylan’s business.Ms. Bresch is a recognized leader in the industry and a vocal champion of initiatives and policy changes aimed at removing access barriers. Among her policy priorities are increasing generic utilization, driving biosimilars interchangeability, stemming the tide of HIV/AIDS, ensuring a fair and a level playing field, and strengthening the global supply chain to make it safer for all patients. Additional details regarding Ms. Bresch’s background can be found on page 11.- Heather Bresch， 自2012年1月1日起，她一直担任Mylan的行政总裁（CEO）。在Mylan公司22年的职业生涯中，她曾在超过15个功能区担任越来越重要的角色。在成为CEO之前，2009年7月她担任Mylan的总裁，负责公司的日常的运作。在此之前，2007年10月至2009年7月她曾担任Mylan公司的首席营运官和首席整合官，引领了两个转型国际并购的成功整合—— Matrix实验室有限公司（Mylan公司实验室有限公司）和Merck KGaA 仿制药和特色制药企业（Merck Generics）。在她的领导下，Mylan公司继续扩大其投资组合及地理覆盖范围，收购可注射的产品和创新的呼吸技术平台的全球领先者；与生物和胰岛素产品组合合作；进入新的商业市场，例如印度和巴西；并通过新颖的测试设备的分布扩大其在艾滋病毒/艾滋病的治疗中的领导地位。
- Heather Bresch has served as Mylan’s CEO since January 1 2012. She continues to lead the next chapter of Mylan’s growth and performance, pursuing a strategy that has produced a sustainable organization that is built for the long-term. Among many other areas of focus, Ms. Bresch is leading a business transformation initiative to further enhance the long-term success and sustainability of the Company, and continues to lead the diversification of the Company in terms of products, markets and channels, a process proven to expand access to the medicines upon which patients depend, while generating durable cash flows that can be reinvested to further differentiate and enhance Mylan’s business.Ms. Bresch is a recognized leader in the industry and a vocal champion of initiatives and policy changes aimed at removing access barriers. Among her policy priorities are increasing generic utilization, driving biosimilars interchangeability, stemming the tide of HIV/AIDS, ensuring a fair and a level playing field, and strengthening the global supply chain to make it safer for all patients. Additional details regarding Ms. Bresch’s background can be found on page 11.
- Kenneth S. Parks
Kenneth S. Parks，自 2021 年 1 月起担任执行副总裁兼首席财务官； 前高级副总裁兼首席财务官 -2020； 前 Mylan N.V。 首席财务官 -2016。
Kenneth S. Parks,Executive Vice President and Chief Financial Officer since January 2021; formerly Senior Vice President and Chief Financial Officer -2020 formerly Chief Financial Officer of Mylan N.V. -2016.- Kenneth S. Parks，自 2021 年 1 月起担任执行副总裁兼首席财务官； 前高级副总裁兼首席财务官 -2020； 前 Mylan N.V。 首席财务官 -2016。
- Kenneth S. Parks,Executive Vice President and Chief Financial Officer since January 2021; formerly Senior Vice President and Chief Financial Officer -2020 formerly Chief Financial Officer of Mylan N.V. -2016.
- Rajiv Malik
Rajiv Malik， 自2012年1月1日起，他曾担任Mylan公司的总裁。此前，他曾在Mylan公司担任多个高级职务，包括2009年7月至2012年12月，担任全球技术运营部主管；2007年1月至2009年7月，担任执行副总裁兼首席营运官。 除了担任总裁监督公司的日常运作外，他一直在识别、评估和执行上有显著业务的发展机会，扩大和优化Mylan的产品组合，并利用Mylan公司的全球研究和开发能力等其他重要的贡献。此前，2005年7月至2008年6月他曾担任Matrix实验室有限公司和Mylan公司实验室有限公司的行政总裁。加入Matrix之前，2003年9月至2005年7月他曾担任Sandoz GmbH公司全球开发和注册的负责人。加入Sandoz之前，1999年10月至2003年9月，他担任Ranbaxy全球法规事务和制药研究部的主管。
Rajiv Malik,Retired President (from the closing of the Combination in 2020 to April 2024), Viatris;President (2012-the closing of the Combination in 2020), Executive Vice President and Chief Operating Officer (2009-2012), Head of Global Technical Operations (2007-2009); joined the company in 2007, Mylan;Chief Executive Officer (2005-2008), Matrix Laboratories Limited (now Mylan Laboratories Limited);Head of Global Development and Registrations (2003-2005), Sandoz GmbH;Head of Global Regulatory Affairs and Head of Pharma Research (1999-2003), Ranbaxy.Public Company Management, Finance, Accounting and Capital Markets, Healthcare Industry, Information Security, Legal and Regulatory Oversight, Risk Oversight/Compliance, Strategy and M&A, and Global Business Experience acquired over his extensive career in the healthcare industry, including at Mylan where he was integral in helping to develop the strategies for the company's acquisitions for over 10 years, as well as the execution and integration of those acquisitions, and was responsible for leading global commercial, scientific, operational, IT and business development activities in more than 165 countries and territories, a portfolio of more than 7,500 products, a pipeline of approximately 1,200 products, and more than 40 manufacturing facilities around the world and further enhanced in his most recent role, where he was responsible for the day-to-day operations of the Company, overseeing the Company's commercial business units, the Commercial Development, Medical, IT and Quality functions, as well as R&D and Operations and where he played a leading role in integrating the two legacy companies while stabilizing the business until his retirement in April 2024.Mr.- Rajiv Malik， 自2012年1月1日起，他曾担任Mylan公司的总裁。此前，他曾在Mylan公司担任多个高级职务，包括2009年7月至2012年12月，担任全球技术运营部主管；2007年1月至2009年7月，担任执行副总裁兼首席营运官。 除了担任总裁监督公司的日常运作外，他一直在识别、评估和执行上有显著业务的发展机会，扩大和优化Mylan的产品组合，并利用Mylan公司的全球研究和开发能力等其他重要的贡献。此前，2005年7月至2008年6月他曾担任Matrix实验室有限公司和Mylan公司实验室有限公司的行政总裁。加入Matrix之前，2003年9月至2005年7月他曾担任Sandoz GmbH公司全球开发和注册的负责人。加入Sandoz之前，1999年10月至2003年9月，他担任Ranbaxy全球法规事务和制药研究部的主管。
- Rajiv Malik,Retired President (from the closing of the Combination in 2020 to April 2024), Viatris;President (2012-the closing of the Combination in 2020), Executive Vice President and Chief Operating Officer (2009-2012), Head of Global Technical Operations (2007-2009); joined the company in 2007, Mylan;Chief Executive Officer (2005-2008), Matrix Laboratories Limited (now Mylan Laboratories Limited);Head of Global Development and Registrations (2003-2005), Sandoz GmbH;Head of Global Regulatory Affairs and Head of Pharma Research (1999-2003), Ranbaxy.Public Company Management, Finance, Accounting and Capital Markets, Healthcare Industry, Information Security, Legal and Regulatory Oversight, Risk Oversight/Compliance, Strategy and M&A, and Global Business Experience acquired over his extensive career in the healthcare industry, including at Mylan where he was integral in helping to develop the strategies for the company's acquisitions for over 10 years, as well as the execution and integration of those acquisitions, and was responsible for leading global commercial, scientific, operational, IT and business development activities in more than 165 countries and territories, a portfolio of more than 7,500 products, a pipeline of approximately 1,200 products, and more than 40 manufacturing facilities around the world and further enhanced in his most recent role, where he was responsible for the day-to-day operations of the Company, overseeing the Company's commercial business units, the Commercial Development, Medical, IT and Quality functions, as well as R&D and Operations and where he played a leading role in integrating the two legacy companies while stabilizing the business until his retirement in April 2024.Mr.
- Anthony Mauro
Anthony Mauro ， 自2012年1月1日起，他一直担任北美Mylan公司的总裁。2009年至2013年2月，他曾担任Mylan制药有限公司的总裁。在Mylan公司的16年里，他曾担任越来越多重要的角色，包括加拿大Mylan制药厂的首席运营官；担任北美Mylan公司的战略发展副总裁；北美销售部的副总裁。
Anthony Mauro,has served as President, Developed Markets since the closing of the Combination on November 16, 2020. His responsibilities include oversight of the commercial functions in more than 35 countries in North America and Europe, including sales and marketing strategies in those regions. From January 2016 until the closing of the Combination, Mr. Mauro served as Chief Commercial Officer of Mylan, with responsibility for overseeing Mylan's commercial businesses around the world. Prior to 2016, Mr. Mauro served as Mylan's President, North America beginning January 1, 2012. He served as President of Mylan Pharmaceuticals Inc. from 2009 through February 2013. Mr. Mauro previously served as Chief Operating Officer of Mylan Pharmaceuticals ULC in Canada, Vice President of North America Strategic Development, and Vice President of North America Sales.- Anthony Mauro ， 自2012年1月1日起，他一直担任北美Mylan公司的总裁。2009年至2013年2月，他曾担任Mylan制药有限公司的总裁。在Mylan公司的16年里，他曾担任越来越多重要的角色，包括加拿大Mylan制药厂的首席运营官；担任北美Mylan公司的战略发展副总裁；北美销售部的副总裁。
- Anthony Mauro,has served as President, Developed Markets since the closing of the Combination on November 16, 2020. His responsibilities include oversight of the commercial functions in more than 35 countries in North America and Europe, including sales and marketing strategies in those regions. From January 2016 until the closing of the Combination, Mr. Mauro served as Chief Commercial Officer of Mylan, with responsibility for overseeing Mylan's commercial businesses around the world. Prior to 2016, Mr. Mauro served as Mylan's President, North America beginning January 1, 2012. He served as President of Mylan Pharmaceuticals Inc. from 2009 through February 2013. Mr. Mauro previously served as Chief Operating Officer of Mylan Pharmaceuticals ULC in Canada, Vice President of North America Strategic Development, and Vice President of North America Sales.